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ABSTRACT 
In the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation 
(ENSURE-AF) study (NCT 02072434), edoxaban showed similar efficacy and safety vs 
enoxaparin–warfarin in patients undergoing electrical cardioversion of nonvalvular atrial 
fibrillation. In this ancillary analysis, we compared the primary efficacy (composite of stroke, 
systemic embolic event, myocardial infarction, and cardiovascular [CV] death, overall study 
period) and safety (composite of major and clinically relevant nonmajor [CRNM] bleeding, on-
treatment) endpoints in relation to body mass index (BMI; <30 vs ≥30 kg/m2). We also 
compared cardioversion outcomes in relation to BMI. Of 2199 patients enrolled, 1095 were 
randomized to edoxaban and 1104 to enoxaparin–warfarin. Mean age was 64±10 and 64±11 
years and mean BMI 30.6 and 30.7 kg/m2, respectively. CV and metabolic diseases were more 
prevalent in obese (n = 1067) than nonobese patients. Overall ischemic event rates were low; 
rates in the BMI <30 kg/m2 subgroup were numerically lower than the ≥30 kg/m2 subgroup, but 
not significantly different (odds ratio [OR], 0.74 [95% confidence interval (CI) 0.23, 2.24]). 
Composite major + CRNM bleeding rates were low and numerically lower, but not significantly 
different (OR 0.88 [0.38,2.04]), between the edoxaban and enoxaparin–warfarin arms and 
across weight categories. Successful cardioversion rate was higher in the BMI <30 vs ≥30 kg/m2 
subgroup (73.9% vs 69.9%; OR 1.22 [1.01-1.48]). In ENSURE-AF, BMI did not significantly impact 
the relative efficacy and safety of edoxaban vs enoxaparin–warfarin. Nevertheless, the 
nonobese group had a higher rate of cardioversion success than the obese group.  
 
Key Words: Body mass index, cardioversion, edoxaban, obesity  
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Introduction 
Obesity is a risk factor for all-cause and cardiovascular (CV) death in the general population; 
however, an inverse relationship between being overweight or obese and a better CV prognosis 
is observed, the so-called “obesity paradox.”1-4    Our recent systematic review was suggestive 
of an obesity paradox in patients with atrial fibrillation (AF), particularly for all-cause and CV 
death outcomes.3  In the nonvitamin K antagonist oral anticoagulant (NOAC) trials of stroke 
prevention in AF, an obesity paradox was also evident, with a treatment effect favoring NOACs 
over warfarin for both efficacy and safety that was significant only for normal-weight 
patients.3,5 Nevertheless, there is uncertainty whether this obesity paradox is also evident for 
AF patients undergoing rhythm control. Certainly, weight reduction is associated with better 
outcomes following rhythm control,6,7 but limited prospective trial data are available.  In the 
Edoxaban Versus Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-
AF) trial, there were comparable low rates of major and clinically relevant nonmajor (CRNM) 
bleeding and thromboembolism when the oral factor Xa inhibitor edoxaban was compared with 
enoxaparin–warfarin.8  This ancillary analysis from the ENSURE-AF trial compared clinical 
outcomes by body mass index (BMI, <30 vs ≥30 kg/m2). 
 
Methods 
The design and principal results of the ENSURE-AF trial (NCT 02072434) have been 
published.8,9 In brief, this was a multicenter, prospective, randomized, open, blinded endpoint 
trial in patients with nonvalvular AF undergoing electrical cardioversion that compared 
edoxaban 60 mg once daily with enoxaparin–warfarin in 2199 patients. Patients with an 
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international normalized ratio (INR) <2.0 at randomization received enoxaparin bridging and 
daily warfarin until the INR was ≥2.0. Those with INR ≥2.0 at the time of randomization did not 
require enoxaparin and were treated with warfarin alone; hence, edoxaban was compared with 
“optimized anticoagulation” with enoxaparin–warfarin. 
The primary efficacy endpoint was the composite of stroke, systemic embolic event 
(SEE), myocardial infarction (MI), and CV death during the overall treatment period from 
randomization until end of study and the primary safety endpoint was the composite of major 
and CRNM bleeding during the on-treatment period (time of first dose to last dose of study 
drug taken). Successful cardioversion was confirmed by 12-lead electrocardiogram-documented 
sinus rhythm. The trial protocol was approved by ethics committees or institutional review 
boards. All patients provided written informed consent prior to participation in the study. This 
ancillary analysis compared the primary efficacy and safety endpoints with clinical outcomes by 
BMI (<30 vs ≥30 kg/m2).  
Patients were followed for 28 days on study drug after cardioversion plus another 30 
days to assess safety, which were analyzed in relation to body weight and BMI. For enoxaparin–
warfarin patients, the clinical characteristics were summarized by BMIs of <30 and ≥30 kg/m2, 
with categorical variables as frequencies and percentages, and continuous variables as mean 
and standard deviation. Comparison of clinical characteristics for patients with BMI <30 and ≥30 
kg/m2 using the chi-square test for categorical variables and 1-way analysis of variance for 
continuous variables were provided.  
The number and percent of patients with primary efficacy and safety outcomes were 
provided by treatment arm. Odds ratios (ORs) and 95% confidence intervals (CIs) are presented 
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to assess the difference between treatment arms. We also explored outcomes in relation to 
BMI as a continuous variable. In addition, successful cardioversion in patients with BMI <30 
kg/m2 were compared with those with BMI ≥30 kg/m2. The number and percent of patients 
with successful cardioversion were provided by BMI category. Odds ratios and 95% CIs are 
presented to assess the difference between BMI categories. 
 
Results 
Of 2199 patients enrolled, 1095 were randomized to edoxaban and 1104 to enoxaparin–
warfarin. Mean ± standard deviation (SD) age was 64.3 ± 10 and 64.2 ± 11 years and mean BMI 
30.6 and 30.7 kg/m2, respectively. In all, 1067 patients had a BMI of ≥30 kg/m2; among these 
obese patients, CV and metabolic diseases were more prevalent than in nonobese patients, as 
confirmed by the use of statins and antihypertension medications (Table 1). Mean CHA2DS2-
VASc (congestive heart failure, hypertension, age ≥75 years [2 points], diabetes mellitus, stroke 
[2 points], vascular disease, age 65–74 years, sex category) and HAS-BLED (hypertension, age, 
stroke, bleeding tendency/predisposition, labile INRs, elderly age/frailty, drugs such as 
concomitant aspirin/nonsteroidal anti-inflammatory drugs or alcohol excess) scores were 
significantly higher in the obese subgroup, suggesting they were at greater risk for stroke and 
bleeding. There were no relevant differences in time to therapeutic range and time in 
therapeutic range in relation to BMI <30 vs ≥30 kg/m2. 
Rates of composite stroke/SEE, MI or CV mortality rates were low and numerically lower 
for obese patients relative to nonobsee patients, but were nonsignificant (OR 0.74 [0.23, 2.24]) 
even for both the edoxaban and enoxaparin–warfarin arms and across weight categories. 
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Composite major and CRNM bleeding rates were low and numerically lower for obese patients 
relative to nonobsese patients (OR 0.88 [0.38, 2.04]), as well as being nonsignificant in both the 
edoxaban and enoxaparin–warfarin arms and across weight categories. Major bleeding rates 
were numerically lower, but nonsignificant across weight categories (OR 0.32 [0.0, 1.8]).  
Successful cardioversion was significantly more likely in those with BMI <30 kg/m2 (OR 
1.22 [1.01–1.48]) (Table 2).  Mean BMI was slightly lower in those with successful cardioversion 
compared to those with unsuccessful cardioversion (30.56 (SD 5.71) vs 31.22 (5.45; p=0.0472). 
In a logistic regression analysis with the composite of major and CRNM bleeding as the 
response variable; and treatment, numerical BMI, and their interaction as independent 
variables; the p-values for treatment, BMI, and interaction were 0.8852, 0.9016, and 0.9662, 
respectively (data not shown).  
When comparing BMI <30 vs ≥30 kg/m2, composite ischemic events (stroke/SEE, MI, and 
CV mortality) were numerically lower, but given the low overall rates, this was nonsignificant 
(on-treatment analysis OR 0.74 [95% CI 0.23, 2.24]). In a logistic regression analysis with 
primary efficacy endpoint as the response variable; and treatment, numerical BMI, and their 
interaction as independent variables; the p-values for treatment, BMI, and interaction were 
0.0645, 0.2022 and 0.1034, respectively (data not shown).  
Outcomes in relation to BMI as a continuous variable are shown in Figure 1. For major 
plus CRNM bleeding (on-treatment analysis), no relationship was apparent between BMI and 
treatment with edoxaban or enoxaparin–warfarin. For stroke/SEE, MI and CV mortality, there 
was a trend toward lower event rates with increasing BMI in the enoxaparin–warfarin group. 
For edoxaban, few events were seen at lower BMI values to show any trends, but no difference 
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was observed when compared with enoxaparin–warfarin at higher BMI values.  The proportion 
with successful cardioversion was higher in the BMI <30 kg/m2 subgroup (827/1119; 73.9%) 
compared with the BMI ≥30 kg/m2 subgroup (745/1067; 69.9%) (OR 1.22 [1.01–1.18]), p  = 
0.038.  In a logistic regression analysis with successful cardioversion as the response variable; 
and treatment, numerical BMI, and their interaction as independent variables; the p-values for 
treatment, BMI, and interaction are 0.7168, 0.2265, and 0.6644, respectively.  
 
Discussion 
In this ancillary analysis from ENSURE-AF, the data suggests that obesity does not 
influence the rate of ischemic events after cardioversion regardless of the therapeutic strategy. 
The BMI <30 kg/m2 group had a higher rate of cardioversion success than the BMI ≥30 kg/m2 
group; and edoxaban had comparable efficacy and safety to optimized usual anticoagulation 
with enoxaparin–warfarin, and were not significantly different in various BMI categories. 
Our systematic review found that only obese patients were at lower risk for major 
bleeding compared with normal-weight patients.3 In the present analysis from ENSURE-AF, no 
significant relationship was evident between the primary bleeding outcome and BMI. The 
present patient population was at low bleeding risk, as evident by a mean HAS-BLED score of 
0.9. While guidelines advocate focus on modifiable bleeding risk factors, recent evidence shows 
that the HAS-BLED score is a better assessment of the AF patient’s potential bleeding risk 
compared with simply using modifiable bleeding risk factors.10-12 
 In a prior systematic review and metaanalysis, we found that there may be 
an obesity paradox in AF patients for all-cause and cardiovascular death outcomes.3 An 
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obesity paradox was also seen for stroke/SEEs, with a treatment effect favoring NOACs over 
warfarin for both efficacy and safety that was significant only for normal-weight patients. In the 
present analysis from ENSURE-AF, obesity did not influence the rate of the composite efficacy 
events (stroke/SEE, MI, and CV mortality) after cardioversion regardless of treatment with 
NOAC or enoxaparin–warfarin. This is despite the ENSURE-AF trial including a relatively high-risk 
patient population for stroke (mean CHA2DS2VASc score 2.6), that was broadly comparable to 
the patient population in the ENGAGE-AF trial13 (mean CHADS2 score 2.8) and other NOAC 
stroke prevention trials.14  Nonetheless, the followup duration in ENSURE-AF was shorter than 
that in the ENGAGE-AF trial. 
As expected from prior studies,15,16 cardioversion success was lower in obese patients. 
This may reflect associated comorbidities or a greater body impedance relevant to ENSURE-AF 
since electrical cardioversion was the only modality used. Indeed, pharmacological 
cardioversion is perhaps more advocated in obese subjects with AF. 
Although the ENSURE-AF trial is the largest study in AF pericardioversion to date, this 
study is limited by being a subgroup analysis of a selected clinical trial cohort, and the results 
may not be applicable to the general AF population. BMI measurement and categorization of 
obesity was based on baseline measures, and changes in BMI over time were not considered. 
Also, the low overall event rates and short follow-up period may have influenced outcome 
event rates, which may be underpowered.  
In conclusion, edoxaban had efficacy and safety comparable with optimized standard 
anticoagulation with enoxaparin-warfarin; neither treatment group showed significant 
differences in various BMI categories. Obesity did not influence the rate of ischemic events 
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after cardioversion regardless of the therapeutic strategy. Nevertheless, the BMI <30 kg/m2 
group had a higher rate of cardioversion success than the obese group.  
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Figure Legend 
 
Figure 1. Event rate at one month of primary efficacy outcomes and BMI for A) Stroke, SEE, MI, 
and CV and B) major or CRNM bleeding . a)  Stroke, SEE, MI, and CV Mortality, ITT Analysis Set - 
Overall Period; b) Stroke, SEE, MI, and CV Mortality, Safety Analysis Set - On Treatment Period. 
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Table 1. Baseline Characteristics by BMI  
 Overall 
BMI (kg/m
2
) 
<30 ≥30  
Variable  
Edoxaban 
(N = 1095) 
Enoxaparin–
warfarin 
(N = 1104) 
Edoxaban 
(n = 560) 
Enoxaparin–
warfarin 
(n = 559) 
Total  
(n = 1119) 
Edoxaban 
(n = 530) 
Enoxaparin–
warfarin 
(n = 537) 
Total  
(n = 1067) p-value
†
 
Age, mean, SD 
 >65  
64.3 (10.3) 
  509 
(46.5%) 
64.2 (10.8) 
530 (48.0%) 
65.6 (11.1) 
293 (52.3%) 
65.1 (11.3) 
287 (51.3%) 
65.4 (11.2) 
580 (51.8%) 
 62.9 (9.3) 
  212 (40.0%) 
63.2 (10.1) 
239 (44.5%) 
63.0 (9.7) 
  451 (42.3%) 
<0.0001 
Weight, kg, mean (SD) 
 ≤60  
90.9 (18.3) 
21 (1.9%) 
91.2 (19.0) 
33 (3.0%) 
79.4 (11.3) 
21 (3.8%) 
78.8 (11.4) 
33 (5.9%) 
79.1 (11.3) 
54 (4.8%) 
102.9 (16.5) 
0 
104.1 (16.6) 
0 
103.5 (16.6) 
0 
<0.0001 
Anticoagulant experienced, n (%) 
 Current
*
 VKA user 
 Current
*
 NOAC user 
 
513 (46.8) 
157 (14.3) 
 
558 (50.5) 
148 (13.4) 
 
257 (45.9) 
78 (13.9) 
 
298 (53.3) 
70 (12.5) 
 
555 (49.6) 
148 (13.2) 
 
254 (47.9) 
77 (14.5) 
 
259 (48.2) 
78 (14.5) 
 
  513 (48.1) 
  155 (14.5) 
 
0.4935 
0.3866 
CrCl, mean (SD) 94.0 (35.7) 94.1 (34.7) 81.2 (29.2) 81.1 (27.9) 81.2 (28.6) 107.5 (37.1) 108.0 (35.9) 107.7 (36.5) <0.0001 
TtTR (days), mean (SD) - 7.7 (5.1) - 7.4 (4.9) - - 7.9 (5.4) - 0.2428 
TiTR (% of time), mean (SD) - 70.8 (27.4%) - 72.0 (26.9) - - 69.8 (28.0) - 0.2153 
TTR (% of time), mean (SD) - 59.8 (30.6%) - 60.5 (30.1) - - 59.3 (31.1) - 0.5646 
 
 Heart Failure 
 Coronary Artery Disease 
 Hypertension 
 Diabetes 
 Peripheral Artery Disease 
 Valvular Heart Disease 
 Intracranial Haemorrhage 
 Ischemic stroke/Transient Ischaemic Attack 
 Myocardial Infarction 
 Life-threatening bleed 
 
476 (43.5%) 
181 (16.5%) 
850 (77.6%) 
218 (19.9%) 
40 (3.7%) 
250 (22.8%) 
2 (0.2%) 
68 (6.2%) 
69 (6.3%) 
3 (0.3%) 
 
484 (43.8%) 
197 (17.8%) 
864 (78.3%) 
197 (17.8%) 
54 (4.9%) 
240 (21.7%) 
3 (0.3%) 
66 (6.0%) 
78 (7.1%) 
3 (0.3%) 
 
219 (39.1%) 
79 (14.1%) 
399 (71.3%) 
80 (14.3%) 
25 (4.5%) 
133 (23.8%) 
0  
41 (7.3%) 
37 (6.6%) 
1 (0.2%) 
 
239 (42.8%) 
93 (16.6%) 
397 (71.0%) 
57 (10.2%) 
30 (5.4%) 
140 (25.0%) 
1 (0.2%) 
39 (7.0%) 
37 (6.6%) 
1 (0.2%) 
 
458 (40.9%) 
172 (15.4%) 
796 (71.1%) 
137 (12.2%) 
55 (4.9%) 
273 (24.4%) 
1 (0.1%) 
80 (7.1%) 
74 (6.6%) 
2 (<0.1%) 
 
256 (48.3%) 
102 (19.2%) 
448 (84.5%) 
137 (25.8%) 
15 (2.8%) 
116 (21.9%) 
2 (0.4%) 
26 (4.9%) 
32 (6.0%) 
2 (0.4%) 
 
245 (45.6%) 
104 (19.4%) 
464 (86.4%) 
139 (25.9%) 
24 (4.5%) 
100 (18.6%) 
2 (0.4%) 
27 (5.0%) 
41 (7.6%) 
2 (0.4%) 
 
501 (47.0%) 
206 (19.3%) 
912 (85.5%) 
276 (25.9%) 
39 (3.7%) 
216 (20.2%) 
4 (0.4%) 
53 (5.0%) 
73 (6.8%) 
4 (0.4%) 
 
0.0051 
0.0174 
<0.0001 
<0.0001 
0.1702 
0.0209 
0.2077 
0.0392 
0.8645 
0.4421 
AF history   
 Paroxysmal (≤7 days) 
 Persistent (>7 days, <1 yr) 
 
208 (19.0%) 
887 (81.0%) 
 
207 (18.8%) 
890 (80.6%) 
 
105 (18.8%) 
455 (81.3%) 
 
115 (20.6%) 
444 (79.4%) 
 
220 (19.7%) 
899 (80.3%) 
 
103 (19.4%) 
427 (80.6%) 
 
92 (17.2%) 
443 (82.8%) 
 
195 (18.3%) 
870 (81.5%) 
 
0.4450 
0.4450 
CHA2DS2-VASc score, mean (SD) 2.6 (1.5) 2.6 (1.4) 2.6 (1.6) 2.5 (1.4) 2.5 (1.50) 2.7 (1.4) 2.7 (1.4) 2.7 (1.4) 0.0101 
HAS-BLED Score, mean (SD) 0.9 (0.8) 0.9 (0.8) 0.9 (0.8) 0.9 (0.8) 0.9 (0.78) 0.8 ( 0.8) 0.9 (0.8) 0.9 (0.8) 0.0361 
Drug therapies 
Aspirin 
Statins  
ACEI/ARB 
Beta blockers 
 
192 (17.5%) 
429 (39.2%) 
692 (63.2%) 
862 (78.7%) 
 
221 (20.0%) 
411 (37.2%) 
688 (62.3%) 
847 (76.7%) 
 
100 (17.9%) 
211 (37.7%) 
322 (57.5%) 
425 (75.9%) 
 
105 (18.8%) 
188 (33.6%) 
308 (55.1%) 
434 (77.6%) 
 
205 (18.3%) 
399 (35.7%) 
630 (56.3%) 
859 (76.8%) 
 
92 (17.4%) 
216 (40.8%) 
368 (69.4%) 
434 (81.9%) 
 
114 (21.2%) 
220 (41.0%) 
376 (70.0%) 
410 (76.4%) 
 
206 (19.3%) 
436 (40.9%) 
644 (60.4%) 
844 (79.1%) 
 
0.5841 
0.0136 
<0.00010.
1975 
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*Current defined as using VKA or NOAC at randomization or within 30 days prior to randomization. Percentages are based on the 
numbers of anticoagulant experienced. 
†Comparisons between total columns for BMI <30 and BMI ≥30.   
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery 
disease; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, stroke (2 points), vascular 
disease, age 65–74 years, sex category; CrCl, creatinine clearance; HAS-BLED, hypertension, age, stroke, bleeding 
tendency/predisposition, labile INRs, elderly age/frailty, drugs such as concomitant aspirin/nonsteroidal anti-inflammatory drugs or 
alcohol excess; HF, heart failure; ICH, intracerebral hemorrhage; MI, myocardial infarction; NOAC, nonvitamin K antagonist oral 
anticoagulant; PAD, peripheral arterial disease; SD, standard deviation; VHD, valvular heart disease; TIA, transient ischemic stroke; 
TiTR, time in therapeutic range (calculated from the first day with 2≤ INR ≤3); TTR, time in therapeutic range (calculated from day 8 
of study drug); TtTR, time to achieve therapeutic range; VKA, vitamin K antagonist. 
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Table 2. Event Rates by BMI 
 
Overall BMI <30 kg/m2 BMI ≥30 kg/m2 
 
Edoxaban 
Enoxaparin–
Warfarin Edoxaban 
Enoxaparin
–Warfarin Edoxaban 
Enoxaparin–
Warfarin 
 
First stroke, SEE, MI, or CV mortality* 
 N 1095 1104 560 559 530 537 
 n (%) 5 (0.5%) 11 (1.0%) 1 (0.2%) 6 (1.1%) 4 (0.8%) 5 (0.9%) 
 OR (95% CI) 0.46 (0.12, 1.43) 0.17 (0, 1.37) 0.81 (0.16, 3.78) 
 
Major or CRNM bleeding events† 
 N 1067 1082 547 551 517 528 
 n (%) 16 (1.5%) 11 (1.0%) 8 (1.5%) 5 (0.9%) 8 (1.6%) 6 (1.1%) 
 OR (95% CI) 1.48 (0.64, 3.55) 1.62 (0.46, 6.34) 1.37 (0.41, 4.82) 
Major bleeding events† 
 N 1067 1082 547 551 517 528 
 N (%)  3 (0.3%)  5 (0.5%) 1 (0.2%) 1 (0.2%) 2 (0.4%) 4 (0.8%) 
 OR (95% CI) 0.61 (0.09, 3.13) 1.01 (0.01, 79.21) 0.51 (0.05, 3.57) 
Successful cardioversion 
 N 1095‡ 1104§ 560 559 530 537 
 n (%) 790 (72.2%) 788 (71.4%) 414 
(73.9%) 
413 (73.9%) 374 (70.6%) 372 (69.3%) 
 OR (95% CI) 1.04 (0.86, 1.26) 1.00 (0.76, 1.32) 1.06 (0.81, 1.39) 
    
  BMI <30 kg/m2 BMI ≥30 kg/m2 
First stroke, SEE, MI, or CV mortality* 
 N  1119 1067 
 n (%)  7 (0.6%) 9 (0.8%) 
 OR (95% CI)  0.74 (0.23, 2.24) 
Major or CRNM bleeding events† 
 N    
 n (%)  1098 1045 
 OR (95% CI)  13 (1.2%) 14 (1.3%) 
  0.88 (0.38, 2.04) 
Major bleeding events† 
 N  1098 1045 
 n (%)  2 (0.2%) 6 (0.6%) 
 OR (95% CI)  0.32 (0.0, 1.8) 
Successful cardioversion‡ 
 N  1119 1067 
 n (%)  827 (73.9%) 746 (69.9%) 
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 OR (95% CI)  1.22 (1.01, 1.48)  
 
*ITT population, overall study period (28 days on study drug after cardioversion + 30 days 
follow-up). 
†All treated patients, on-treatment period (time of first dose to last dose of study drug taken). 
BMI, body mass index; CI, confidence interval; CRNM, clinically relevant nonmajor; CV, 
cardiovascular; ITT, intention to treat; MI, myocardial infarction; OR, odds ratio; SEE, systemic 
embolic event.  
‡Data for BMI was not available for 5 patients. 
§Data for BMI was not available for 8 patients. 
 
 
